Medical Device News Magazine

Saturday, April 1, 2023

Brett Swansiger Hired As Chief Commercial Officer at DxTerity

DxTerity Reports Brett Brings 20 Years Plus of Commercial Leadership, International Business Development, and Managed Care Contracting Experience

Brett Swansiger has been hired to serve as Chief Commercialization Officer at DxTerity.

As Chief Commercial Officer and SVP of Managed Care, Brett Swansiger will be responsible for building DxTerity’s US market position by identifying, developing, and negotiating strategic business partnerships with life-science organizations as well as establishing government and commercial payer contracts for DxTerity testing. This includes establishing strategic alliances, companion diagnostic development programs, intellectual property (in/out) licensing, and joint ventures that fit within DxTerity’s overall corporate strategy.

Brett Swansiger brings over 20 years of commercial leadership, international business development, and managed care contracting experience within the molecular diagnostics and pharmaceutical industries. Prior to joining DxTerity, he held multiple commercial leadership positions at MDxHealth Inc., a multi-national urologic oncology company, including VP of Managed Care and Payer Strategy, SVP International Business Development & European Sales, and SVP of US Sales & Integrated Healthcare Systems.

Brett Swansiger has had significant success with establishing licensing and clinical study contracts with diagnostic and pharmaceutical market leaders as well as getting key integrated healthcare systems like Kaiser Permanente, the Veteran’s Administration, the Department of Defense, and Geisinger to adopt new molecular diagnostic testing pathways. Prior to joining MDxHealth, Brett was Vice President of Managed Care and Asia Market Access for Agendia Inc., and he held multiple commercial leadership positions at Prometheus Laboratories Inc., a Nestlé Health Science company that focuses on personalized medicine for autoimmune disorders.

“We are excited to have Brett Swansiger on board. Over the last year, DxTerity has made tremendous progress in bridging the power of precision medicine to autoimmune disease. Our type 1 interferon (IFN-1) test for systemic lupus erythematous (SLE), the most common form of lupus, has been shown to be a significant predictor of a patient’s risk of developing lupus nephritis (p=0.0008) and it is being used extensively by pharmaceutical companies in clinical trials. The IFN-1 test is now available for patient use, and Brett’s experience with obtaining reimbursement and contracting with manage care organizations will play a pivotal role in this testing being adopted by the medical community across the US,” according to Bob Terbrueggen, Founder and CEO of DxTerity Diagnostics.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.
Subscribe to Medical Device News Magazine

Dr Azeem Latib, World-Renowned Interventional Cardiologist, to Join the Leadership Team of Supira Medical

Dr Azeem Latib, has joined the company as Medical Director to advance clinical activities and prepare the company for significant clinical and regulatory milestones.

By using this website you agree to accept Medical Device News Magazine Privacy Policy